Therapeutics Uses of Psychedelics in patients with psychiatric disorders A Systematic Review
Sarosh Nawaz, Abdulaziz Mohammed Althwanay, Esraa M. Aledani Mb Ch B, Harleen Kaur, Malik Kasapoglu, Rajesh Yadavalli, Ann Kashmer Yu
Journal For International Medical Graduates April 18, 2024 Peer reviewed DOI: 10.56570/jimgs.v1i1.155 via OpenAlex
Summary
Psychedelics like LSD, psilocybin, and mescaline may improve conditions such as depression, anxiety, PTSD, and existential distress in cancer patients. The review highlights their action on 5-HT2A receptors, producing varied effects on consciousness and mood. Despite promising results from pilot studies and randomized controlled trials, the optimal models for their use in psychiatry remain debated.
Study at a glance
| Design | systematic review |
|---|---|
| Population | patients with psychiatric diseases |
| Key finding | Psychedelics have shown effective improvement in psychiatric diseases in many pilot studies and randomized controlled trials. |
Abstract
The impact of psychedelic treatment on patients suffering from psychiatric diseases like depression, anxiety, post-traumatic psychiatric disorder (PTSD), and existential distress related to cancer has become very intriguing to psychiatrists in the modern era. Serotonergic psychedelics include Lysergic acid diethylamide (LSD), psilocybin, mescaline, ayahuasca, and methylene-deoxy methamphetamine (MDMA) which act agonistically on 5-hydroxytryptamine type 2-A (5-HT2A) receptors. Psychedelics produce a wide range of effects, based on varying sites of 5-HT2a receptors, including changes in consciousness, perception, mood, and behaviour. Psychedelics can lead to both good and bad trips depending on the dose and environment in which it is taken. We used systematic approach by strictly following Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) 2020 guidelines. Data is extracted from pub med using mesh strategy, and from google scholar and science direct by using keywords. 10 review articles are selected by using quality appraisal tools. The purpose of this paper is to highlight the mechanism of action and role of psychedelics in patients with mental health disorders. In this review, we discussed the effective models of neurodynamical changes produced by psychedelics, and we also show that these substances can be used as a potential treatment option for psychiatric patients. Psychedelics have shown effective improvement in psychiatric diseases in many pilot studies and randomized controlled trials. There is still a debate going on about which models best suggest their role in the field of psychiatry.